MENU
+Compare
INTS
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$0.31
Change
-$0.00 (-0.00%)
Capitalization
8.45M

INTS Intensity Therapeutics Forecast, Technical & Fundamental Analysis

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers... Show more

INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for INTS with price predictions
Jun 27, 2025

INTS in +6.67% Uptrend, rising for three consecutive days on June 27, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INTS advanced for three days, in of 81 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INTS's RSI Indicator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INTS as a result. In of 42 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INTS broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INTS entered a downward trend on June 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.000) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). INTS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.247).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

INTS is expected to report earnings to fall 27.27% to -15 cents per share on August 18

Intensity Therapeutics INTS Stock Earnings Reports
Q2'25
Est.
$-0.16
Q1'25
Missed
by $0.04
Q4'24
Missed
by $0.95
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.04
The last earnings report on May 13 showed earnings per share of -21 cents, missing the estimate of -18 cents. With 12.67K shares outstanding, the current market capitalization sits at 8.45M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1 Enterprise Drive
Phone
+1 203 221-7381
Employees
17
Web
https://www.intensitytherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLBX5.900.15
+2.61%
Blackboxstocks
CG51.170.50
+0.99%
Carlyle Group (The)
CDP27.93N/A
N/A
COPT Defense Properties
DCTH13.57-0.48
-3.42%
Delcath Systems
SES0.89-0.06
-5.85%
SES AI Corp

INTS and Stocks

Correlation & Price change

A.I.dvisor tells us that INTS and GBIO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and GBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
N/A
GBIO - INTS
29%
Poorly correlated
-15.40%
MRKR - INTS
29%
Poorly correlated
N/A
ACAD - INTS
28%
Poorly correlated
-0.41%
GPCR - INTS
27%
Poorly correlated
N/A
CCCC - INTS
27%
Poorly correlated
-7.89%
More